Cellectis (NASDAQ:CLLS) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.
This table compares Cellectis and Titan Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Cellectis has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.
This is a summary of current ratings and target prices for Cellectis and Titan Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cellectis presently has a consensus price target of $35.25, indicating a potential upside of 117.86%. Titan Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 227.87%. Given Titan Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Titan Pharmaceuticals is more favorable than Cellectis.
Insider and Institutional Ownership
30.6% of Cellectis shares are held by institutional investors. Comparatively, 5.1% of Titan Pharmaceuticals shares are held by institutional investors. 16.4% of Cellectis shares are held by insiders. Comparatively, 6.5% of Titan Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Cellectis and Titan Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cellectis||$21.43 million||31.41||-$78.69 million||($1.93)||-8.38|
|Titan Pharmaceuticals||$6.62 million||2.49||-$9.02 million||($0.79)||-1.54|
Titan Pharmaceuticals has lower revenue, but higher earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Titan Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Cellectis beats Titan Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Cellectis Company Profile
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm. It is also developing UCARTCLL1 to treat AML; ALLO-819 for treating AML; UCARTCS1 for the treatment of multiple myeloma (MM); and ALLO-715 to treat MM. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; Cornell University; Dana Farber Cancer Institute; and H. Lee Moffitt Cancer Center. Cellectis S.A. was founded in 1999 and is based in Paris, France.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.